United States
Germany
Japan
United Kingdom
China
LRRFIP2 (NM_006309) Human Tagged ORF Clone Lentiviral Particle
CAT＃: RC224063L1V
- LentiORF®
-
Lenti ORF particles, LRRFIP2 (Myc-DDK-tagged)-Human leucine rich repeat (in FLII) interacting protein 2 (LRRFIP2), transcript variant 1, 200ul, >10^7 TU/mL
Need custom lentivirus service?
Get a free quote
CNY 13,680.00
货期*
详询
规格
Product images
经常一起买 (3)
Specifications
| Product Data | |
| Product Name | LRRFIP2 (NM_006309) Human Tagged ORF Clone Lentiviral Particle |
| Synonyms | HUFI-2 |
| Vector | pLenti-C-Myc-DDK |
| ACCN | NM_006309 |
| ORF Size | 2163 bp |
| Sequence Data |
The ORF insert of this clone is exactly the same as(RC224063).
|
| OTI Disclaimer | The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info |
| OTI Annotation | This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene. |
| Reference Data | |
| RefSeq | NM_006309.1 |
| RefSeq Size | 2412 bp |
| RefSeq ORF | 2166 bp |
| Locus ID | 9209 |
| MW | 82 kDa |
| Gene Summary | The protein encoded by this gene, along with MYD88, binds to the cytosolic tail of toll-like receptor 4 (TLR4), which results in activation of nuclear factor kappa B signaling. The ubiquitin-like protein FAT10 prevents the interaction of the encoded protein and TLR4, thereby inactivating the nuclear factor kappa B signaling pathway. In addition, this protein can downregulate the NLRP3 inflammasome by recruiting the caspase-1 inhibitor Flightless-I to the inflammasome complex. [provided by RefSeq, Jan 2017] |
Documents
| Product Manuals |
| FAQs |
| SDS |
Resources
You may also need
其它LRRFIP2产品
Customer
Reviews
Loading...
